REWIND

The REWIND CVOT assessed the cardiovascular safety of dulaglutide in patients with type 2 diabetes with high CV risk, or prior CV events. This module details the results.

REWIND
Rate this content
  • REWIND
  • REWIND
  • REWIND
  • REWIND: trial design
  • REWIND: key inclusion and exclusion criteria
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go